BioCentury | May 28, 2019
Company News

Months after scuttling IPO bid, Centrexion adds to balance sheet with Lilly deal for pain therapy

...$950 million in milestones. The deal gives Eli Lilly and Co. (NYSE:LLY) oral SSTR4 agonist CNTX-0290...
...Transient receptor potential A1; TRPV1 (VR1) - Transient receptor potential vanilloid 1 Mark Zipkin, Staff Writer CNTX-0290 Centrexion...
BioCentury | Apr 4, 2016
Company News

Boehringer Ingelheim, Centrexion Therapeutics deal

...Centrexion acquired from Boehringer pain compounds CNTX-6970 , CNTX-6016 and CNTX-0290 . CNTX-6970, a selective cytokine...
...a selective cannabinoid CB2 receptor (CNR2) agonist, is in preclinical testing to treat neuropathic pain. CNTX-0290...
...testing to treat mixed nociceptive and neuropathic pain. Centrexion expects clinical testing of CNTX-6016 and CNTX-0290...
BioCentury | Mar 31, 2016
Company News

Centrexion acquires Boehringer pain compounds

...selective cannabinoid CB2 receptor ( CNR2 ) agonist Boehringer has studied in neuropathic pain; and CNTX-0290...
Items per page:
1 - 3 of 3